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PURPOSE. This study investigated the effects of the tumor sup-
pressor protein PTEN (phosphatase and tensin homolog) on
transforming growth factor (TGF)-1–mediated signaling path-
ways and the transdifferentiation of human subconjunctival
fibroblasts (SCFs) after the transduction of this protein contain-
ing a transactivator of transcription (Tat) domain.
METHODS. The Tat-PTEN expression vector was constructed to
express the Tat domain of HIV-1 fused to PTEN. After trans-
duction of the fusion protein and TGF-1 stimulation, the
dose-dependent effect of the transduced Tat-PTEN fusion pro-
tein on Akt phosphorylation and the stability of the Tat-PTEN
fusion protein in SCF cells were evaluated by Western blot
analysis. The effect of the Tat-PTEN fusion protein on the
TGF-1–stimulated expression of -SMA and fibronectin was
also evaluated by Western blot analysis and immunocytochem-
istry.
RESULTS. To increase the efficiency of enzyme activity and to
successfully deliver this protein to cells, the authors used a
PTEN fusion protein that contained the transduction domain of
the Tat protein from HIV-1. By Western blot analysis, the
transduced Tat-PTEN fusion protein was found to modulate
TGF-1 signaling in SCF cells and result in the suppression of
Akt phosphorylation. Furthermore, the transduction of the
Tat-PTEN fusion protein was found to suppress the TGF-1–
stimulated expression of -SMA and fibronectin by Western
blot analysis and immunocytochemical staining, and the effects
of the transduced fusion protein could be controlled in a
dose-dependent manner.
CONCLUSIONS. The Tat-PTEN fusion proteins were successfully
transduced into the SCF cells and induced the suppression of
transdifferentiation and fibrosis through the regulation of TGF-
–mediated signaling. The ability of the Tat-PTEN fusion pro-
tein to regulate cell survival could potentially be applied to
protein therapy to counteract postoperative scarring in glau-
coma surgery. (Invest Ophthalmol Vis Sci. 2012;53:379–386)
DOI:10.1167/iovs.11-8491
In the eye, failed glaucoma filtration surgery arises from thedevelopment of subconjunctival fibrosis, which results in
conjunctival scarring from the wound healing process.1–3
Transforming growth factor beta (TGF-) is a key mediator
of wound healing and is critically involved in postoperative
scarring.4,5 At the cellular level, TGF- drives the conversion of
fibroblasts into myofibroblasts, which is a key step for all
fibrotic processes.6 This transdifferentiation is characterized by
the de novo synthesis of alpha-smooth muscle actin (-SMA).7
The persistence of the myofibroblasts is associated with an
increased deposition of extracellular matrix (ECM) proteins
and leads to tissue fibrosis.8,9 Therefore, TGF- is a major target
in the development of antifibrotic treatment strategies, and
intracellular signaling pathways downstream of TGF- may
provide additional therapeutic targets. Importantly, the inhibi-
tion of p38- or Rho-dependent signaling has been shown to
inhibit myofibroblast transdifferentiation in vitro.10–12
Among the signaling pathways triggered by TGF-, the
phosphoinositide 3-kinase (PI3K)/Akt pathway that regulates a
variety of cellular processes, including cell proliferation, me-
tabolism, migration, and survival, is involved in the establish-
ment of fibrotic fibroblasts by opposing the functions of phos-
phatase and tensin homolog (PTEN).13–15 PTEN is a tumor
suppressor gene located at chromosome 10q23.3, and dele-
tions or mutations within the PTEN gene have been reported in
various forms of human cancer.16–18 The PTEN protein is a
protein phosphatase and a lipid phosphatase and is therefore
considered a dual specificity phosphatase.19 As a lipid phos-
phatase, PTEN acts as a tumor suppressor and a phosphatidyl-
inositol-3 phosphatase to downregulate the activity of phos-
phoinositol-3-kinase, which is important for the regulation of
cell proliferation, growth, and survival.20–22
Previous studies have reported that the transactivator of
transcription (Tat) from HIV-1 has the capacity to cross cell
membranes.23,24 Recently, HIV-1 Tat proteins have been
shown capable of transducing many heterologous proteins,
such as p16, p27, E2F, Cdk2, and SOD, across the cell mem-
brane, although the exact delivery mechanisms are not
known.25–30 In this study, subconjuctival fibroblast cells stim-
ulated with TGF- served as a model of the antagonistic scar-
ring process, and Tat-PTEN fusion proteins were developed to
investigate the role of PTEN in this system.
MATERIALS AND METHODS
Cell Cultures and Chemicals
Human subconjunctival fibroblasts were obtained from the Tenon
capsule as previously described.31 This research followed the tenets of
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the Declaration of Helsinki. Written informed consent was obtained
before the operative excision of these cells, and approval from the
institutional human experimentation committee was also granted. The
subconjunctival fibroblast cells were cultured at 37°C in a 5% humid-
ified CO2 environment and in a culture medium containing Dulbecco’s
modified Eagle’s medium that was supplemented with 10% fetal bovine
serum, 50 g/mL penicillin, and 50 g/mL streptomycin. The cells
used for these studies had been passaged between three and six times.
TGF-1 was purchased from a commercial supplier (R&D Systems,
Minneapolis, MN), and the concentration of TGF-1 that was used to
directly treat the culture medium was 10 ng/mL.
Expression and Purification of the Tat-PTEN
Fusion Protein
The Tat-PTEN expression vector was designed to express the Tat
domain of HIV-1 fused to PTEN, as described by Nagahara et al.30 Two
oligonucleotides were synthesized to generate 11 amino acids of the
Tat domain flanked by glycine residues. The sequences of top strands
were 5-(ggatcc)GGT TAC GGT CGT AAG AAA CGT AGA CAG CGC
AGA CGT GGT(c)-3, and the sequences of bottom strands were
5-(ctcgag)ACC ACG TCT GCG CTG TCT ACG TTT CTT ACG ACC GTA
CCA-3. The nucleotides in parentheses were included to form BamHI
and XhoI restriction sites. The synthesized double-stranded oligonu-
leotide was inserted into a BamHI- and XhoI-digested pRSET vector
(Invitrogen, San Diego, CA), which had an N-terminal polyhistidine
(6xHis) tag for purification and epitope identification (Xpress using the
anti-Xpress antibody). Next, the human PTEN gene was inserted into
the pRSET vector and the Tat domain was inserted in-frame to create
the Tat-PTEN expression vector.
The open reading frame of human PTEN was amplified using a
human cDNA library (Stratagene, La Jolla, CA) as the template. The PCR
primers were synthesized using the GenBank database of PTEN
(u93051) as a reference. The sequence of the top strand of PTEN was
5-(aaa-ctc-gag)ATG ACA GCC ATC ATC AAA GA-3, and the sequence
of the bottom strand was 5-(aaa-aag-ctt)TCA GAC TTT TGT AAT TTG
TGT ATG CTG-3. Both the top-strand and the bottom-strand se-
quences had XhoI and HindIII restriction sites, which were indicated
in parentheses, for subcloning into the pRSET vector that contained
the Tat domain. The PCR amplifications were performed using a
precision Taq polymerase (TaqPlus; Clontech, Palo Alto, CA), and the
PCR consisted of 25 cycles of 94°C for 30 seconds, 62°C for 30
seconds, and 68°C for 1 minute. The PCR products were purified and
cloned into the TA cloning vector (Promega). The sequences of the
inserts from the selected colonies were confirmed by sequence anal-
ysis with a DNA analyzer system (ABI 3100; PerkinElmer, Waltham,
MA). Once more, the selected TA cloning vector was digested with
XhoI and HindIII and was then relegated into the Tat-containing pRSET
expression vector that had been previously digested with XhoI and
HindIII. The Tat-PTEN construct and the PTEN pRSET construct were
then transformed into E. coli BL21 (DE3). The fusion proteins were
purified according to the slightly modified protocols from Becker-
Hapak et al.32 The selected BL21 colony was cultured in 3 mL of
L-Broth (LB) medium overnight. The next day, the BL21 culture was
inoculated into 1 L of LB medium and cultured until an OD600 was
attained. Next, 1 mM of IPTG (isoprophyl-1-thio--D-galactopyranoide)
was added and incubated for 8 hours at 37°C for the overexpression of
the fusion protein. After the culture medium was centrifuged at
10,000g for 10 minutes, the bacterial pellets that contained the PTEN
or Tat-PTEN proteins were suspended in 20 mL of binding buffer
without urea (5 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9)
and were sonicated. The disrupted cells were centrifuged at 14,000g
for 20 minutes, and then the pellets were resuspended in buffer A (8
M urea, 5 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9) for
further purification. The resuspended sonicates were applied to a
preequilibrated histidine binding resin (Novagen) with distilled water,
charge buffer (50 mM NiSO4), and binding buffer and were allowed to
flow by gravity. Next, the column was washed with 10 volume equiv-
alents of binding buffer and with 6 volume equivalents of wash buffer
(20 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9) and elution
buffer (100 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9). The
fusion proteins were eluted using elution buffer with increasing con-
centrations of imidazole that ranged from 250 to 500 mM. After
purification, preequilibrated PD-10 columns (Amersham Pharmacia
Biotech AB, Uppsala, Sweden) and serum-free media were used to
change the media. The concentration of the purified fusion protein
was determined by a protein assay procedure (Bradford) using bovine
serum albumin as the standard. The purified fusion proteins were
stored at 80°C in serum-free media that contained 3% glycerol.
Transduction of the Tat-PTEN Fusion Protein and
TGF-1 Treatment
For the transduction of the Tat-PTEN fusion protein, subconjuctival
fibroblast cells were grown to confluence. Before treatment with the
fusion proteins, the cells were serum-starved in serum-free media for 2
hours. Next, the media was replaced with serum-free media that
contained the fusion proteins, and the transduction period lasted for 2
hours. After the transduction of the fusion proteins, the samples were
washed twice with serum-free media to eliminate any remaining fusion
protein. For the stimulation with TGF-1, 10 ng/mL TGF-1 was
directly added to the cells in serum-free media, and this treatment
lasted for 48 hours. After the transduction and TGF-1 stimulation, the
cells were harvested for Western blot analysis.
Next, the effects of the Tat-PTEN fusion protein on fibronectin and
-SMA activity after TGF-1 stimulation were evaluated. After 2 hours
of transduction with Tat-PTEN, the cells were either treated with
TGF-1 or left untreated, and then the samples were analyzed by
Western blot and immunocytochemistry using antibodies against fi-
bronectin and -SMA.
Western Blot Analysis
The cells were washed twice with ice-cold PBS and were then lysed in
cold 1  cell lysis buffer, which consisted of 20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1% Triton X-100, 1 mM Na2EDTA, 1 mM EGTA, 1 mM
PMSF, 1 g/mL leupeptin, 1 mM Na3VO4, 2.5 mM sodium pyrophos-
phate, and 1 mM -glycerophosphate (Cell Signaling Technology, Dan-
vers, MA), by sonication for 10 minutes on ice. The protein concen-
tration was determined using a protein assay procedure (Bradford
reagent; Sigma). The protein was loaded onto the appropriate percent-
age of SDS-PAGE gel and was then transferred onto a nitrocellulose
membrane. The membrane was incubated with a primary antibody at
4°C overnight. The primary antibodies used in these experiments
included anti-phospho-Akt (Ser473), anti-Akt, anti-phospho-JNK anti-
body, anti-JNK antibody, anti-phospho-P38 antibody, anti-P38 antibody
(Cell Signaling Technology), anti-phospho-ERK antibody, anti-ERK an-
tibody (Santa Cruz Biotechnology), anti-phospho-Smad2 antibody (Mil-
lipore), anti-Smad2/3 (BD Transduction Laboratory), epitope identifi-
cation antibody (Anti-Xpress; Invitrogen), anti-PTEN (Santa Cruz
Biotechnology), and anti-cellular fibronectin (Sigma-Aldrich). After a
washing step, the membranes were incubated with HRP-conjugated
sheep anti-mouse IgG or anti-rabbit IgG (Amersham Pharmacia Bio-
tech) secondary antibodies for 1 hour at room temperature. The
protein signals were detected using a Western blot detection reagent
(ECL Reagent; Amersham Pharmacia Biotech).
Immunocytochemistry
Subconjunctival fibroblasts that had attached to the chamber slides
were washed and then fixed in 4% (v/v) formaldehyde for 5 minutes at
room temperature. The cells were permeabilized by a 5-minute treat-
ment with 0.05% (v/v) Triton X-100 in PBS. After the cells were washed
with cold PBS, the Tat-PTEN staining, which consisted of the addition
of the anti-epitope identification antibody (Xpress) followed by the
FITC-conjugated antibody, was performed overnight at 4°C. The nuclei
were stained with DAPI and incubated for 15 minutes at room tem-
perature. The cells were then washed with binding buffer (10 mM
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HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, and 1.8 mM
CaCl2) and mounted. The cells were imaged using a confocal micro-
scope and a laser scanning microscope (Zeiss LSM-510) with an optical
slice of 0.8 m. The cells were incubated overnight at 4°C with the
appropriate fibronectin (Santa Cruz Biotechnology) and -SMA
(DAKO) primary antibodies that were diluted 1:100 in PBS. The cells
were subsequently incubated with FITC-conjugated anti-mouse IgG
(Vector Laboratories) secondary antibodies, which were diluted 1:100
in PBS for 2 hours at room temperature in the dark. The cells were then
washed three times with PBS and viewed using immunofluorescence
microscopy (IX71 instrument; Olympus). Negative controls were rou-
tinely included and consisted of cells that were incubated in normal
buffered serum without the primary antibody.
RESULTS
Cloning of the Human PTEN Gene and the
Construction of the Expression Vector
As an initial step in the production of cell-permeable PTEN
fusion proteins, the PTEN gene was amplified from the human
cDNA library by PCR using the Pfu DNA polymerase. For the
overexpression and purification of the Tat fusion proteins, we
constructed a Tat-PTEN expression vector that contained the
Tat protein transduction domain and the cDNA sequence en-
coding human PTEN (Tat-PTEN). In addition, we constructed a
PTEN expression vector without the Tat protein transduction
domain to test the permeability of intact PTEN. Each expres-
sion vector had six histidine residues as well as epitope iden-
tification residues (Xpress) at the amino terminus for protein
purification and detection by Western blot analysis.
Expression and Purification of the Tat-PTEN and
PTEN Proteins
After overexpression of the fusion proteins in E. coli BL21
(DE3), the Tat-PTEN, PTEN, and Tat-SOD fusion proteins were
purified by affinity chromatography using a metal chelating
matrix under urea-denaturing conditions. The Tat-PTEN and
PTEN proteins were purified from the inclusion bodies of the
bacterial cells. The Tat-PTEN and PTEN purified products were
determined by SDS-PAGE analysis with Coomassie brilliant blue
staining (Fig. 1A), which was further confirmed by Western
blot (using an anti-Xpress antibody) (Fig. 1B). The Tat-PTEN
fusion proteins migrated at an approximately 5-kDa increased
molecular weight than the PTEN protein due to the presence
of the Tat transduction domain.
Transduction of Tat-PTEN into Cultured Human
Subconjunctival Fibroblasts
To analyze the ability of the Tat-PTEN fusion protein to trans-
duce into human conjunctival fibroblast cells, 1 M of the
purified Tat-PTEN fusion proteins were added to the human
SCF culture media for 2 hours, and the levels of the transduced
proteins in the cells were determined by Western blot. In
Figure 2A, the control cells are shown in lane 1, and the cells
transduced with the Tat-PTEN fusion protein and immunoblot-
ted with the anti-PTEN antibody are shown in lane 2. The
results indicated that the Tat-PTEN fusion proteins were effi-
ciently transduced into the SCF cells and that human SCF cells
appear to have low baseline PTEN expression levels. The cell
transduction capacity of the Tat domain was confirmed using
an epitope identification antibody (Anti-Xpress), as shown in
Figure 2B. The Tat-PTEN protein was efficiently delivered to
subconjuctival fibroblasts, whereas no bands were detected
from cells that received the control or the PTEN without the
Tat domain. To determine the transduction efficiency of Tat-
PTEN, the Tat-PTEN fusion proteins were added to the cells at
increasing concentrations for a 2-hour transduction period. As
a result, the Tat-PTEN protein was transduced into the cells in
a dose-dependent manner, and the transduction was most
effective at the 2-M protein concentration (Fig. 2C). The
nuclei were stained with DAPI, and the TAT-PTEN fusion pro-
teins were stained (using the Anti-Xpress antibody) for immu-
nofluorescence analysis (Fig. 2D).
Next, we sought to determine the extent to which the
Tat-PTEN fusion proteins were maintained in the transduced
cells. To do this, the Tat-PTEN fusion proteins were added to
cells in a time-dependent manner. After serum starvation for 2
hours, 1 M of the Tat-PTEN fusion protein was added to the
cells for a 2-hour transfection period. Then, the cells were
consecutively harvested after another 30 minutes, 5 hours, 24
hours, 48 hours, or 72 hours in culture. The stability of the
transduced proteins was analyzed by Western blot (using the
FIGURE 1. Cloning and purification of
the Tat-PTEN fusion proteins in E. coli
and their transduction into the SCF cells.
A diagram for the controlled expression
of PTEN and Tat-PTEN fusion proteins.
The coding frame of human PTEN is
represented by an open box and the
6His and the HIV-1 Tat basic domains
(RKKRRQRRR) are shown (A). Syn-
thetic oligomers that corresponded to
Tat were cloned into the BamHI and
XhoI sites of the pRSET A vector to
make Tat, and then human PTEN cDNA
was cloned into the XhoI and HindIII
sites of Tat. The resulting vector was
named Tat-PTEN. The expression vector
was under the control of the T7 pro-
moter and ATG-RBS. Expression was in-
duced by the addition of IPTG. Ampicil-
lin, selection of the plasmid; F1 Ori,
single-strand rescue of DNA; pUC ori,
replication and growth (B). Purified fu-
sion proteins were detected by Coo-
massie brilliant blue staining on a
10% SDS-PAGE gel (C) and were im-
munoblotted with a mouse monoclo-
nal IgG1 antibody (D).
IOVS, January 2012, Vol. 53, No. 1 Tat-PTEN Modulated TGF- Signaling in Fibroblasts 381
Anti-Xpress antibody). After the initial transduction period of 2
hours, the transduced proteins were found at the highest level
after another 30 minutes in culture, and their levels decreased
gradually thereafter. However, the Tat-PTEN proteins persisted
in the SCF cells for at least an additional 72 hours (Fig. 3).
Effect of Dose-Dependent Transduction of
Tat-PTEN Fusion Proteins on Akt Phosphorylation
and Tat-PTEN Fusion Protein Stability in SCF Cells
We previously demonstrated TGF-1–induced Akt phosphory-
lation in SCF cells.33 Therefore, in this experiment, we inves-
tigated the effect of TGF-1 stimulation on the PI3K/Akt sig-
naling pathway in Tat-PTEN–transduced SCF cells. The cells
were harvested for Western blot analysis after the Tat-PTEN
transduction and TGF-1 stimulation. Treatment with TGF-1
resulted in Akt phosphorylation, and the Tat-PTEN proteins
that were transduced into the cells downregulated these TGF-
1–mediated changes (Fig. 4A). The total levels of these pro-
teins were not affected by PTEN transduction or TGF-1 stim-
ulation, which indicated that PTEN fusion proteins modulate
TGF-–mediated signaling in SCF cells. The phosphorylation of
Akt was downregulated by transduction of the Tat-PTEN fusion
proteins in a dose-dependent fashion (Fig. 4B). The phosphor-
ylation states of ERK1/2 and Smad2/3 were not definitely al-
tered after the transduction of the fusion proteins (Fig. 4C).
Effect of the Tat-PTEN Fusion Proteins on
TGF-1–Stimulated Expression of -SMA and
Fibronectin in Human SCF Cells
TGF- is known to drive the conversion of fibroblasts into
myofibroblasts, which is a key step for all fibrotic processes.6
To analyze the effect of the Tat-PTEN fusion protein on TGF-
1–stimulated expression of -SMA and fibronectin in human
SCF cells, 1 M of the fusion protein was added to the human
SCF cell culture media. After 2 hours of fusion protein trans-
duction, the cells were treated with or without TGF-1, and
expressions of -SMA and fibronectin were analyzed. The
Western blot analysis and immunocytochemical staining dem-
onstrated that the transduction of the Tat-PTEN fusion protein
reduced the expression of both -SMA and fibronectin in the
SCF cells (Figs. 5A, 5B).
DISCUSSION
Excess scarring of the conjunctiva after glaucoma filtration
surgery is a major cause of the failure of surgical treat-
ments.3,34 Treatment with antimetabolites, such as mitomy-
cin C and 5-fluorouracil, could decrease the frequency of
scar formation and improve the surgical outcome. However,
these drugs could be associated with serious complications
such as bleb leakage, hypotonus maculopathy, and infective
endophthalmitis.35,36 Moreover, the response of individual
patients to these agents can be idiosyncratic, making dose
titration difficult.37 These findings prompted us to consider
the need for novel agents that can efficiently increase the
surgical outcome with less toxicity and fewer complica-
tions.
FIGURE 2. Transduction of Tat-PTEN into the SCF cell. After 2 hours of transduction with 1 M of Tat-PTEN or PTEN, the transduction of the SCF
cells was analyzed by Western blot using an anti-PTEN antibody (A) and a mouse monoclonal IgG1 antibody (B). The SCF cells were treated with
0.25, 0.5, 1, and 2 M of the Tat-PTEN fusion proteins for 2 hours and were then immunoblotted using the mouse monoclonal IgG1 antibody. The
levels of the proteins increased depending on the concentration of Tat-PTEN (C). Immunofluorescence staining of the TAT-PTEN transduced
subconjunctival fibroblasts. The nuclei were stained with DAPI, and TAT-PTEN was stained with monoclonal IgG1 antibody (D).
FIGURE 3. Stability of the Tat-PTEN fusion proteins in the SCF cells.
After a transfection with 1 M of Tat-PTEN protein, the level of
transduced protein peaked at 30 minutes and persisted for 72 hours.
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The conversion of fibroblasts into myofibroblasts, which are
the cellular protagonists of fibrosis, requires the cytokine TGF-
.12 TGF- is a major target of current antifibrotic treatment
strategies, as approaches using scavenging antibodies, endog-
enous antagonists, and nucleotide-based methods have been
demonstrated.5,38–40 The PI3K/Akt pathway is a downstream
mediator of TGF- signaling that is involved in the establish-
ment of fibrotic fibroblasts, and its activity is antagonized
directly by PTEN, which dephosphorylates PIP3 at the D3
position of the inositol ring.13–15,21 In light of these findings,
we assessed the effect of Tat-PTEN fusion protein transduction
on TGF-–induced myofibroblast transdifferentiation. Our data
FIGURE 4. The effects of Tat-PTEN transduction on the phosphorylation of Akt in SCF cells stimulated by TGF-1. After 2 hours of Tat-PTEN
transduction, the cells were treated with or without TGF-1 and were then immunoblotted using an anti-phospho-Akt antibody. The phospho-Akt
that was stimulated by TGF-1 was downregulated after the transduction of the Tat-PTEN fusion proteins into the SCF cells. (A) The dose-dependent
effect of Tat-PTEN fusion protein transduction on the phosphorylation of Akt by the SCF cells. The phospho-Akt (Ser473) that was stimulated by
TGF-1 was downregulated in a dose-dependent manner by the transduction of the Tat-PTEN fusion proteins, irrespective of Akt expression (B).
TGF-1 also elevated the phosphorylation states of ERK1/2, p38, JNK, and Smad 2/3, which were not altered after the transduction of the fusion
proteins (C). Results are representative of those in three repeated experiments.
IOVS, January 2012, Vol. 53, No. 1 Tat-PTEN Modulated TGF- Signaling in Fibroblasts 383
indicate that transduction with the Tat-PTEN fusion protein
blocks this process in human SCF cells through the inhibition
of the PI3K/Akt signaling pathway.
For this study, we used TGF-1–stimulated SCF cells that
had been transduced with Tat-PTEN fusion proteins in vitro as
a model for the antiscarring process.41–43 To transfer and
control the enzymatic activity of PTEN in cells, we developed
the Tat domain transduction approach for protein delivery that
has been previously described.30 The purified Tat-PTEN fusion
protein efficiently entered the SCF cell within the 2-hour initial
treatment period, although the PTEN protein without the Tat
domain could not. The level of fusion protein transduction into
the SCF cells could be increased in a dose-dependent manner,
and the peak transduction was determined to occur at a pro-
tein concentration of 2 M.
Of the signaling pathways that are triggered by TGF-1,
mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated kinase 1/2 (ERK1/2) activation has been shown to be
involved in the TGF-1–induced phenotypic transformation of
human lung fibroblasts into myofibroblasts.44,45 Furthermore,
the activity of the phosphoinositide 3-kinase/Akt pathway,
which regulates a wide variety of cellular processes, including
cell proliferation, metabolism, migration, and survival, is also
involved in the establishment of fibrotic fibroblasts by inhibit-
FIGURE 5. Effect of Tat-PTEN fusion
protein on the TGF-1–stimulated
expression of -SMA and fibronectin
in human SCF cells. After 2 hours of
fusion protein transduction (1 M),
the cells were treated with or with-
out TGF-1, and expressions of
-SMA and fibronectin were ana-
lyzed. The transduction of the Tat-
PTEN fusion proteins significantly re-
duced the expression of both -SMA
and fibronectin in the SCF cells as
assessed by immunoblotting (A) and
immunocytochemical staining (B).
Results are representative of those in
three repeated experiments.
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ing the functions of PTEN.13–15 To investigate the signals that
are involved in the modulation of TGF-1 signaling by the
Tat-PTEN fusion protein, we examined the phosphorylation
status of key molecules that are involved in proliferation sig-
naling pathways by Western blot. The addition of TGF-1 (10
ng/mL) elevated the phosphorylation status of Akt, ERK1/2,
and p38 MAPK. These results confirm previous findings that
have demonstrated that the mitogenic activity of TGF- results
in fibroblast-mediated collagen contraction, proliferation, and
migration.46,47 The phosphorylation states of ERK1/2, JNK,
p38, and Smad2/3 were not definitely altered after the trans-
duction of the fusion proteins. However, the transduction of
the Tat-PTEN fusion proteins decreased the TGF-1–stimulated
expression of phospho-Akt. The phosphorylation status of Akt
was lower in the absence of TGF-1 than for the control, and
this was regardless of whether the levels of these proteins were
constant. These results imply that exogenous PTEN protein
can effectively block the TGF-1 signal.
As shown here and in previous reports, the activity of
PI3K/Akt is antagonized directly by PTEN. PTEN has been
implicated in myofibroblast transdifferentiation because dis-
tinct inhibition or loss of PTEN expression in fibroblasts has
been correlated with -SMA expression from lung biopsy sam-
ples from patients with idiopathic pulmonary fibrosis or usual
interstitial pneumonia. In vitro, myofibroblast differentiation
has also been shown to be inhibited by PTEN, and the in vivo
inhibition of PTEN promotes fibrosis.13–15,48 To evaluate the
influence of an exogenous Tat-PTEN fusion protein on TGF-
1–stimulated structural changes in SCF cells, we assessed the
expression of the myofibroblast markers -SMA and fibronec-
tin. Tat-PTEN fusion protein transduction inhibited TGF-1–
stimulated myofibroblast differentiation and ECM production,
and this was determined by Western blotting and by immuno-
cytochemical staining for -SMA and fibronectin. White et al.14
also demonstrated that myofibroblasts have diminished PTEN
expression, that inhibition of PTEN in vivo promotes fibrosis,
and that PTEN inhibits myofibroblast differentiation in vitro.
As a model system representing the antiscarring process in
subconjunctival fibroblasts, we developed a fusion protein that
consisted of the PTEN tumor suppressor gene fused to the Tat
transduction domain of HIV-1. Our results indicated that the
Tat-PTEN fusion protein was successfully delivered into the
cells, whereby it suppressed the transdifferentiation of human
SCF cells by modulating TGF-1 signaling in a relatively short
time period. Nagahara et al.30 reported the ability of TAT-
p27Kip1 proteins to be transduced directly into almost 100% of
primary or transformed cells, and this resulted in induced cell
migration and represented arbitrary control over the intracel-
lular processes. The potent capacity of the Tat-PTEN fusion
proteins to suppress myofibroblastic transdifferentiation could
potentially be very useful for protein therapy. Although gene
therapy relies on the transfer of a viral or nonviral vector into
cells, this method using a Tat-PTEN fusion protein does not rely
on a vector and could be easily adapted for use with a variety
of cell types and for applications such as cancer therapy. The
exact mechanism behind the inhibition of TGF-1–mediated
transdifferentiation in SCF cells remains to be elucidated by
further investigations. However, our results should encourage
further in vivo studies regarding efficacy, toxicity, and the
potential role of Tat-PTEN fusion protein as a means to prevent
bleb failure in glaucoma filtration surgery.
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